title: Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
abstract: OBJECTIVE
  We evaluated the efficacy and safety of a twice-daily dosage regimen of cisapride 20 mg in relieving the symptoms of mild-moderate gastroesophageal reflux disease (GERD) in patients with moderate intensity heartburn and no history of erosive esophagitis.
  
  
  METHODS
  After a 2-wk, single-blind, placebo run-in period, 398 patients who continued to experience moderate intensity heartburn were randomized to either placebo (n = 196) or cisapride 20 mg (n = 202) twice daily for 4 wk.
  
  
  RESULTS
  Compared with placebo, cisapride significantly reduced scores for daytime and nighttime heartburn (p < 0.001), total regurgitation (p < 0.001), eructation (p = 0.04), and early satiety (p = 0.04). Cisapride 20 mg b.i.d. was also superior to placebo in reducing total use of rescue antacid medication (p < 0.001); reducing, in concordance analyses, daytime and nighttime heartburn with antacid usage (p < 0.001); increasing the percentage of heartburn-free days and antacid-free nights (p < 0.5); and increasing the percentage of patients self-rated as having minimal or better symptomatic improvement (p = 0.01). Cisapride 20 mg b.i.d. was well tolerated. The most common adverse event in the cisapride group was diarrhea, reported by 10% of patients, compared with an incidence of 4% in the placebo group.
  
  
  CONCLUSIONS
  Cisapride 20 mg b.i.d. was shown to be effective and safe for the short-term treatment of daytime and nighttime heartburn and for other symptoms associated with mild-moderate GERD.
authors.affiliation: Allegheny University Hospitals, Philadelphia, Pennsylvania 19146, USA.
authors.forename: D O
authors.initials: DO
authors.lastname: Castell
authors.forename: C
authors.initials: C
authors.lastname: Sigmund
authors.forename: D
authors.initials: D
authors.lastname: Patterson
authors.forename: R
authors.initials: R
authors.lastname: Lambert
authors.forename: D
authors.initials: D
authors.lastname: Hasner
authors.forename: C
authors.initials: C
authors.lastname: Clyde
authors.forename: J B
authors.initials: JB
authors.lastname: Zeldis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000863:Antacids / Q000008:administration & dosage; D020117:Cisapride; D004884:Eructation / Q000188:drug therapy; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006356:Heartburn / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D016037:Single-Blind Method
chemical_list: D000863:Antacids; D005765:Gastrointestinal Agents; D010880:Piperidines; D020117:Cisapride